Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience.
- Author:
Li ZHANG
1
;
null
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bone Marrow; drug effects; Camptothecin; adverse effects; analogs & derivatives; therapeutic use; Female; Humans; Intestinal Neoplasms; drug therapy; Male; Middle Aged
- From: Chinese Journal of Oncology 2003;25(6):607-609
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of campto (CPT-11) monotherapy or combined with 5Fu + leucovorin (CF) in advanced large intestinal cancer.
METHODS186 such patients were divided into campto monotherapy group and CPT-11 plus 5Fu + CF [De Gramont (DGM) or Mayo protocal] groups. The mean dose of CPT-11 was 270 mg/m(2) alone in the monotherapy group and 150 mg/m(2) in the combination group. Campto was given as iv infusion in no less than 30-minutes.
RESULTS186 patients were eligible for response evaluation. The response rates were 27.9% in the monotherapy group, 32.7% in CPT-11 + DGM and 27.3% in CPT-11 + Mayo group. For 55 untreated patients, the response rates of monotherapy, Campto + DGM and Campto + Mayo regime groups were 33.3%, 28.9% and 50.0%. For 131 treated patients, they were 26.4%, 34.8% and 22.2%, respectively. The toxicities of the whole group were 16.0% cholinergic syndrome, 51.9% delayed diarrhea and 19.8% leucopenia. There were 2 treatment-related deaths.
CONCLUSIONThe efficacy and toxicities of campto are similar as compared with the reports by other investigators.
